Pediatric Glioblastoma Multiforme (GBM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Pediatric Glioblastoma Multiforme (GBM) Market Outlook

Thelansis’s “Pediatric Glioblastoma Multiforme (GBM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pediatric Glioblastoma Multiforme treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Pediatric Glioblastoma Multiforme (GBM) Overview

Glioblastoma multiforme (GBM) is a formidable disease, comprising 17% of adult intracranial neoplasms. No identified risk factors are associated with GBM, except for exposure to ionizing radiation. GBM is one of the most aggressive forms of cancer in humans. Despite advancements in surgical techniques and additional treatments, the average survival time remains approximately 1 year. In adults, GBM is the most prevalent type of astrocytoma and is typically associated with a grim prognosis, with a median survival of about 12 months. However, it is rare in children. Around 65% of GBM cases primarily manifest in the cerebral hemispheres, which govern higher cognitive functions such as speech, movement, thought, and sensation. GBMs can also arise in other regions of the brain that regulate sensory perception, temperature sensitivity, balance, and motor function. The most prevalent symptoms of GBM include morning headaches, lethargy, and seizures that vary depending on the type and location of the tumor. Compression of neighboring brain structures due to the tumor's position can result in motor dysfunction, hormonal irregularities, or changes in behavior and cognitive processes. GBMs are typically diagnosed between the ages of 5 and 9, affecting both boys and girls equally. However, they occur more frequently in children with specific genetic syndromes, including neurofibromatosis 1, Li-Fraumeni syndrome, hereditary nonpolyposis colon cancer, and tuberous sclerosis. The majority of GBM cases, however, have an unknown cause. Treatment options for GBM may encompass neurosurgery, radiation therapy, and chemotherapy.

• Glioblastoma multiforme is the most aggressive malignant primary brain tumor, with an incidence of 2–3 per 100,000 people in the United States and Europe. In children, accounting for only 3% of childhood brain tumors.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: